Hiroshi Ishiguro

6PUBLICATIONS
17CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 19, 2026
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.

Norikazu Masuda, Hiroyuki Yasojima, Hiroko Bando

|Mar 31, 2023
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).

Kenichi Watanabe, Naoki Niikura, Yuichiro Kikawa

|Oct 23, 2020
Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial.

Moe Tsuda, Hiroshi Ishiguro, Naoko Toriguchi

|Mar 15, 2020
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.

Hiroshi Ishiguro, Norikazu Masuda, Nobuaki Sato

|Feb 09, 2019
Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.

Hiroshi Ishiguro, Shinji Ohno, Yutaka Yamamoto

|Nov 14, 2017
A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).

Hiroshi Ishiguro, Shigehira Saji, Shogo Nomura

Pageof 1

Frequent Collaborators

2 joint publications

Norikazu Masuda

1 joint publications

Toshimi Takano

1 joint publications

Hiroyuki Yasojima

1 joint publications

Hiroko Bando